Product
Carboplatin + Paclitaxel
Aliases
Carboplatin and Paclitaxel, Carboplatin/ Paclitaxel
8 clinical trials
27 indications
Indication
Head and Neck Squamous Cell CarcinomaIndication
High Grade Serous OvarianIndication
fallopian tubeIndication
Primary Peritoneal CancerIndication
Endometrial CancerIndication
Salivary Gland CancerIndication
Ovarian Neoplasm EpithelialIndication
Fallopian Tube NeoplasmsIndication
Endometrioid CarcinomaIndication
High-grade Serous Ovarian CarcinomaIndication
NSCLCIndication
Ovarian CancerIndication
Neoplasms by SiteIndication
Genital NeoplasmsIndication
WomanIndication
CancerIndication
Glandular and EpithelialIndication
NeoplasmsIndication
cancerIndication
Epithelial Ovarian CancerIndication
Ovarian DiseasesIndication
Genital DiseasesIndication
Endocrine System DiseasesIndication
AnlotinibIndication
AngiogenesisIndication
Antineoplastic AgentsIndication
Tyrosine Kinase InhibitorClinical trial
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2)Status: Active (not recruiting), Estimated PCD: 2023-09-07
Clinical trial
TAK-676 Alone and in Combination(s) With Carboplatin, 5-Fluorouracil, and Paclitaxel in Patients With Head and Neck Squamous Cell CarcinomaStatus: Completed, Estimated PCD: 2022-11-15
Clinical trial
A Pilot Study of Nivolumab With or Without Ipilimumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
Phase II Study of Concurrent and Sequential Carboplatin and Paclitaxel With Adjuvant Radiotherapy for High Risk Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)Status: Active (not recruiting), Estimated PCD: 2023-08-23
Clinical trial
The "Upproach" Approach: A Phase 2 Study Of Upfront Intensity Modulated Proton Beam Therapy (Impt) And Concurrent Chemotherapy For Post-Operative Treatment In Loco-Regionally Advanced Endometrial CancerStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
OV PRECISION: A Randomized Controlled Swiss Trial Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy in Ovarian Cancer.Status: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Prospective, Single-arm, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2025-09-30